Spine technology company NuVasive Inc (NASDAQ: NUVA) declared on Monday that it received 510(k) clearance from the US Food and Drug Administration (FDA) for the use of its Precice all-internal limb lengthening solution to include pediatric patients over 12 years of age.

The company said Precice is designed by its NuVasive Specialized Orthopedics (NSO) division, which is is focused on the design and innovation of disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening. The device is a magnetically adjustable technology that utilises an external remote to non-invasively lengthen implants.

NuVasive added that the Precice nail has been implanted more than 15,000 times by more than 2,000 surgeons. It is used in nearly 50 countries.